176 related articles for article (PubMed ID: 28943437)
1. Inhibiting prenylation augments chemotherapy efficacy in renal cell carcinoma through dual inhibition on mitochondrial respiration and glycolysis.
Huang J; Yang X; Peng X; Huang W
Biochem Biophys Res Commun; 2017 Nov; 493(2):921-927. PubMed ID: 28943437
[TBL] [Abstract][Full Text] [Related]
2. Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy.
Chen D; Sun X; Zhang X; Cao J
J Biochem Mol Toxicol; 2018 Sep; 32(9):e22195. PubMed ID: 30004155
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage.
Zhu M; Li Y; Zhou Z
Biochem Biophys Res Commun; 2017 Oct; 492(3):373-378. PubMed ID: 28847725
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mitochondrial translation effectively sensitizes renal cell carcinoma to chemotherapy.
Wang B; Ao J; Yu D; Rao T; Ruan Y; Yao X
Biochem Biophys Res Commun; 2017 Aug; 490(3):767-773. PubMed ID: 28645610
[TBL] [Abstract][Full Text] [Related]
5. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
[TBL] [Abstract][Full Text] [Related]
6. Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism.
Teh JT; Zhu WL; Ilkayeva OR; Li Y; Gooding J; Casey PJ; Summers SA; Newgard CB; Wang M
Oncogene; 2015 Jun; 34(25):3296-304. PubMed ID: 25151967
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol-lowering drug pitavastatin targets lung cancer and angiogenesis via suppressing prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signaling.
Hu T; Shen H; Huang H; Yang Z; Zhou Y; Zhao G
Anticancer Drugs; 2020 Apr; 31(4):377-384. PubMed ID: 32011362
[TBL] [Abstract][Full Text] [Related]
8. Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein Kinase 1α-Dependent Inhibition of Wnt/β-Catenin.
Cui L; Zhao J; Liu J
Am J Med Sci; 2018 Mar; 355(3):274-280. PubMed ID: 29549930
[TBL] [Abstract][Full Text] [Related]
9. Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.
Hagiwara N; Watanabe M; Iizuka-Ohashi M; Yokota I; Toriyama S; Sukeno M; Tomosugi M; Sowa Y; Hongo F; Mikami K; Soh J; Fujito A; Miyashita H; Morioka Y; Miki T; Ukimura O; Sakai T
Cancer Lett; 2018 Sep; 431():182-189. PubMed ID: 29778569
[TBL] [Abstract][Full Text] [Related]
10. HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.
Huang J; Zhao X; Li X; Peng J; Yang W; Mi S
PLoS Biol; 2021 Apr; 19(4):e3001197. PubMed ID: 33905408
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin Reduces Cancerogenic Potential of Renal Cancer Cells via Geranylgeranyl Pyrophosphate and Mevalonate Pathway.
Woschek M; Kneip N; Jurida K; Marzi I; Relja B
Nutr Cancer; 2016; 68(3):420-7. PubMed ID: 27042994
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways.
Pan Q; Xu J; Ma L
Fundam Clin Pharmacol; 2020 Feb; 34(1):32-40. PubMed ID: 31058344
[TBL] [Abstract][Full Text] [Related]
13. Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells.
David JM; Owens TA; Barwe SP; Rajasekaran AK
Mol Cancer Ther; 2013 Nov; 12(11):2296-307. PubMed ID: 24006494
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas.
Isono T; Chano T; Yonese J; Yuasa T
Sci Rep; 2016 May; 6():25669. PubMed ID: 27157976
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Sirt3 supports cell proliferation by regulating glutamine-dependent oxidation in renal cell carcinoma.
Choi J; Koh E; Lee YS; Lee HW; Kang HG; Yoon YE; Han WK; Choi KH; Kim KS
Biochem Biophys Res Commun; 2016 Jun; 474(3):547-553. PubMed ID: 27114304
[TBL] [Abstract][Full Text] [Related]
16. mTOR activation is critical for betulin treatment in renal cell carcinoma cells.
Cheng W; Ji S; Zhang H; Han Z; Liu Q; Wang J; Ping H
Biochem Biophys Res Commun; 2017 Jan; 482(4):1030-1036. PubMed ID: 27908730
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline sensitizes renal cell carcinoma to chemotherapy by preferentially inhibiting mitochondrial translation.
Wang B; Ao J; Li X; Yu W; Yu D; Qiu C
J Int Med Res; 2021 Oct; 49(10):3000605211044368. PubMed ID: 34644207
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
19. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
Yagi S; Aihara K; Ikeda Y; Sumitomo Y; Yoshida S; Ise T; Iwase T; Ishikawa K; Azuma H; Akaike M; Matsumoto T
Circ Res; 2008 Jan; 102(1):68-76. PubMed ID: 17967781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
